comparemela.com

Latest Breaking News On - Alkem laboratories limited - Page 8 : comparemela.com

Introducing agility into HR is now a leadership prerogative

Introducing agility into HR is now a leadership prerogative
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

CIPLA, Sun Pharmaceuticals Share Prices Today: Pharma Stocks Rally On High Demand Of Medicines Amid Rising COVID-19 Cases

Pharmaceutical stocks today: Nifty Pharma gained 3.13 per cent at 13,006.85 points. Share prices of pharmaceutical stocks such as Cipla Limited and Sun Pharmaceuticals rallied on Friday, April 9, due to the growing demand of medicines and related products amid the second wave of the COVID-19 pandemic in the country. Cipla gained around five per cent and Sun Pharmaceutical Industries gained around four per cent in the session today. Among sectoral indices, Nifty Pharma gained 3.13 per cent at 13,006.85 points. On Friday, Cipla opened on the NSE at Rs 840.90, touching an intra day high of Rs 892.30 and an intra day low of Rs 836.65, in the session so far. Whereas, Sun Pharmaceuticals opened on the NSE at Rs 613, touching an intra day high of Rs 642 and an intra day low of Rs 609.50.

Generic Drugs Market Revenue Worth $786 Billion by 2030 says P&S Intelligence

Generic Drugs Market Revenue Worth $786 Billion by 2030 says P&S Intelligence NEW YORK, March 17, 2021 /PRNewswire/ Almost 75% of the deaths in 2020 were because of chronic diseases, as per the World Health Organization (WHO). Among the diseases, the deadliest were ischemic heart disease, diabetes, cancer, and stroke. This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030. This is because branded drugs are often expensive, which is why a large number of people in developing countries are not able to purchase them. Generic drugs, on the other hand, are cost-effective, at the same time contain the same active ingredients and have a similar effect as patented drugs. In this regard, the generic drugs market is also being driven by the patent expiry of blockbuster medications. As patented drugs lose their certification, it gives pharmaceutical companies the opportunity to

Alkem makes Epilepsy Treatment more accessible & affordable with the launch of BRIVASURE (Brivaracetam)

Mumbai (Maharashtra) [India], March 15 (ANI/NewsVoir): Alkem Laboratories Ltd. (Alkem), one of India s leading pharmaceutical formulation development, manufacturing, and marketing companies in India, announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India. Epilepsy is a common neurological disorder. Of the 70 million persons with epilepsy (PWE) worldwide, nearly 12 million PWE are expected to reside in India; which contributes to nearly one-sixth of the global burden.1 Brivaracetam has shown promise in patients with epilepsy whose seizures persist despite adequate treatment. The drug offers improved seizure control with minimal safety risks for patients with epilepsy2 Alkem Laboratories Limited has introduced brand Brivasure, the brand of Brivaracetam, at an affordable price in India.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.